These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22001539)

  • 1. Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form.
    Fujii Y; Kanamaru T; Kikuchi H; Nakagami H; Yamashita S; Akashi M; Sakuma S
    Int J Pharm; 2011 Dec; 421(2):244-51. PubMed ID: 22001539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enteric-coated tablets improve oral bioavailability of DX-9065, a novel anticoagulant.
    Fujii Y; Kanamaru T; Kikuchi H; Yamashita S; Sakuma S
    Eur J Pharm Sci; 2011 Mar; 42(4):392-9. PubMed ID: 21238588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclodextrins improve oral absorption of a novel factor Xa inhibitor by interfering with interaction between the drug and bile acids in rats.
    Fujii Y; Takahashi M; Ishiguro T; Sakuma S; Uekama K; Irie T
    J Pharm Pharmacol; 2013 Nov; 65(11):1598-606. PubMed ID: 24118066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.
    Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
    Semin Thromb Hemost; 1996; 22(3):255-9. PubMed ID: 8836010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.
    Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Nagamochi M; Kobayashi S; Komoriya S; Yokomizo A; Muto R; Yamaguchi M; Osanai K; Suzuki M; Kanno H
    Bioorg Med Chem; 2009 Feb; 17(3):1193-206. PubMed ID: 19128974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
    Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
    Thromb Haemost; 1994 Sep; 72(3):392-6. PubMed ID: 7855790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
    Tanabe K; Morishima Y; Shibutani T; Terada Y; Hara T; Shinohara Y; Aoyagi K; Kunitada S; Kondo T
    Thromb Haemost; 1999 May; 81(5):828-34. PubMed ID: 10365760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant.
    Fujii Y; Takahashi M; Morita H; Kikuchi H; Aramaki Y; Amidon GL
    Drug Metab Pharmacokinet; 2007 Feb; 22(1):26-32. PubMed ID: 17329908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
    Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
    J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
    Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of administration site in the gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal.
    Sakuma S; Tanno FK; Masaoka Y; Kataoka M; Kozaki T; Kamaguchi R; Kokubo H; Yamashita S
    J Control Release; 2007 Mar; 118(1):59-64. PubMed ID: 17250919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
    Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
    Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DX-9065a Daiichi.
    Kaiser B
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1105-12. PubMed ID: 14582456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system.
    Hoffart V; Lamprecht A; Maincent P; Lecompte T; Vigneron C; Ubrich N
    J Control Release; 2006 Jun; 113(1):38-42. PubMed ID: 16697485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
    Hara T; Yokoyama A; Tanabe K; Ishihara H; Iwamoto M
    Thromb Haemost; 1995 Aug; 74(2):635-9. PubMed ID: 8584999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
    Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
    J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of cholestyramine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Frey R; Wetzelsberger N; Lücker PW; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):250-4. PubMed ID: 9208341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.